{"transactions":[{"id":1790827,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:39.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023."}],"balance_after":8500,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001493152-23-031538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223031538/ownership.xml","form_type":"4"}},{"id":2175357,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.81,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175356,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.53,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175355,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.93,"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175354,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.99,"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175353,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.1,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175352,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.19,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175351,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.24,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175350,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.69,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175349,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":10.84,"underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175348,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":13500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6,"underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2175347,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-24T20:18:06.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":500,"price":6.23,"value":3115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029651/doc4.xml","form_type":"4"}},{"id":2214645,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2022-07-05T20:05:57.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022."}],"balance_after":100000,"derivative":{"exercise_price":0.255,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-22-018526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222018526/ownership.xml","form_type":"4"}},{"id":2435287,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T21:00:13.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":30000,"derivative":{"exercise_price":4.81,"expiration_date":"2032-01-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-003403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003403/doc4.xml","form_type":"4"}},{"id":2495219,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T21:06:41.000Z","date":"2021-11-22","kind":"purchase","acquired":true,"shares":3000,"price":0.7423,"value":2226.9,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-21-046043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321046043/doc4.xml","form_type":"4"}},{"id":2561963,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:31:21.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000905718-21-001219","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821001219/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2947304,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-14T16:18:09.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years."}],"balance_after":30000,"derivative":{"exercise_price":4.53,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000920465-20-000162","document":"wf-form4_160798067443413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046520000162/wf-form4_160798067443413.xml","form_type":"4"}},{"id":2949752,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T16:05:22.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":16.52,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-062688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589362/000120919120062688/doc4.xml","form_type":"4"}},{"id":3028417,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T00:59:17.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020."}],"balance_after":120000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000905718-20-000961","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000961/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3333014,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-23T16:09:15.000Z","date":"2019-12-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on December 20, 2020."}],"balance_after":12000,"derivative":{"exercise_price":3.93,"expiration_date":"2029-12-20","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000182","document":"wf-form4_157713533716932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000182/wf-form4_157713533716932.xml","form_type":"4"}},{"id":3343392,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-12T18:21:43.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":30.51,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-060279","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589362/000120919119060279/doc4.xml","form_type":"4"}},{"id":3687278,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T21:57:28.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 23, 2020."}],"balance_after":12000,"derivative":{"exercise_price":5.99,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000019","document":"wf-form4_154847143154709.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000019/wf-form4_154847143154709.xml","form_type":"4"}},{"id":3707367,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-03T20:08:32.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":12500,"derivative":{"exercise_price":14.08,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-001523","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589362/000120919119001523/doc4.xml","form_type":"4"}},{"id":3740716,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-06T16:17:14.000Z","date":"2018-12-03","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest with respect to 25% of the underlying shares on 12/03/2019, with the remaining shares vesting in equal monthly installments\nover the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":35000,"derivative":{"exercise_price":15.79,"expiration_date":"2028-12-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-061249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589362/000120919118061249/doc4.xml","form_type":"4"}},{"id":3911450,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-01T21:12:32.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":500,"price":6,"value":3000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares."}],"balance_after":13500,"derivative":{"exercise_price":6,"expiration_date":"2023-11-21","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000920465-18-000019","document":"wf-form4_152790193416176.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000019/wf-form4_152790193416176.xml","form_type":"4"}},{"id":3911449,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T21:12:32.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":500,"price":6,"value":3000.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0000920465-18-000019","document":"wf-form4_152790193416176.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000019/wf-form4_152790193416176.xml","form_type":"4"}},{"id":4114247,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T21:55:43.000Z","date":"2017-12-29","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options represent a right to purchase a total of  18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares."}],"balance_after":14000,"derivative":{"exercise_price":6,"expiration_date":"2023-11-21","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000920465-18-000002","document":"wf-form4_151503452964254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000002/wf-form4_151503452964254.xml","form_type":"4"}},{"id":4114246,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T21:55:43.000Z","date":"2017-12-29","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years."}],"balance_after":0,"derivative":{"exercise_price":10.84,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000920465-18-000002","document":"wf-form4_151503452964254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000002/wf-form4_151503452964254.xml","form_type":"4"}},{"id":4114245,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:55:43.000Z","date":"2017-12-29","kind":"sale","acquired":false,"shares":10000,"price":32.3208,"value":323208.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000920465-18-000002","document":"wf-form4_151503452964254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000002/wf-form4_151503452964254.xml","form_type":"4"}},{"id":4114244,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:55:43.000Z","date":"2017-12-29","kind":"exercise","acquired":true,"shares":4000,"price":6,"value":24000.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000920465-18-000002","document":"wf-form4_151503452964254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000002/wf-form4_151503452964254.xml","form_type":"4"}},{"id":4114243,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:55:43.000Z","date":"2017-12-29","kind":"exercise","acquired":true,"shares":6000,"price":10.84,"value":65040.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000920465-18-000002","document":"wf-form4_151503452964254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046518000002/wf-form4_151503452964254.xml","form_type":"4"}},{"id":4133859,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-13T21:05:36.000Z","date":"2017-12-11","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on December 11, 2018."}],"balance_after":10000,"derivative":{"exercise_price":28.1,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000077","document":"wf-form4_151321712188537.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000077/wf-form4_151321712188537.xml","form_type":"4"}},{"id":4496947,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Douglass Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T18:23:13.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 4, 2018."}],"balance_after":10000,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000016","document":"wf-form4_148374497590317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000016/wf-form4_148374497590317.xml","form_type":"4"}}]}